Harsha Deshmukh has been appointed a member of the Board of Managing Directors with responsibility for IT and Global Business Services effective 1 February 2026 Boehringer Ingelheim announced today that the Shareholders’ Committee has appointed Harsha Deshmukh to the Board of Managing Directors. Effective 1 February 2026, Harsha Deshmukh will lead the IT and Global Business Services [...]
The European Medicines Agency’s (EMA’s) Committee for Veterinary Medicinal Products (CVMP) has adopted positive opinions for two Boehringer poultry vaccines against the highly pathogenic H5 avian influenza virus1. VAXXITEK® HVT+IBD+H5 is the first trivalent vaccine offering combined protection against Marek’s disease, Infectious Bursal Disease and H5 avian influenza in chickens and turkeys in one single [...]
Ingelheim, Germany, May 6, 2025 (Korea Bizwire) – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a potential first-in-class treatment for geographic atrophy (GA).[1] Geographic atrophy (GA) is an eye disease that can lead to irreversible vision loss.[2] It affects more than [...]
Ingelheim, Germany and Amsterdam, the Netherlands, 23 April 2025 (Korea Bizwire) – Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into a research collaboration and global license agreement. Jointly the partners will focus on the development of first-in-class, oral precision treatments for people living [...]
Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The agreement focuses on further research and development of a novel, first-in-class bispecific compound for T cell mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases. The candidate compound has the potential to [...]
VAXXITEK® HVT+IBD+H5 is a new trivalent vaccine for poultry that offers protection against Marek’s disease, Infectious Bursal Disease and H5 avian influenza in just one shot. H5 avian influenza is a highly contagious and notifiable zoonotic disease, that is currently having a heavy impact on the poultry industry, farmers, and international trade worldwide. Administration at the [...]
Ingelheim, Germany, 20 February 2025 – Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, gene therapy aiming to improve disease outcomes in people with cystic fibrosis (CF), regardless of gene mutations that are causing the disease. The [...]
Ridgefield, Conn., U.S., and Ingelheim, Germany Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved The application for this investigational treatment is based on positive results from the Phase Ib Beamion LUNG-1, Cohort 1 trial that demonstrated an objective response [...]
Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 versus placebo The FIBRONEER™-ILD trial is the second Phase III trial in which the investigational compound nerandomilast has met its primary endpoint1 Initial safety and tolerability [...]
·More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1 ·DRD is a growing epidemic that is expected to increase as the incidence of diabetes escalates across the globe.2,3 ·There is an urgent need for earlier detection of DRD [...]